2015-12-23

[#DIV28SUPER] National Institute on Drug Abuse Request for Applications (RFAs) for HIV/AIDS research

Table of Contents:

 

I.      NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding

(NOT-OD-15-137)

National Institutes of Health

Office of AIDS Research

2.    Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01)
(RFA-DA-16-012)
National Institute on Drug Abuse
Application Receipt Date(s): March 02, 2016

3.    Systems Biology Approaches in HIV/AIDS and Substance Use (R01)
(RFA-DA-16-013)
National Institute on Drug Abuse
Application Receipt Date(s): April 04, 2016

4.    Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01)
(RFA-DA-16-014)
National Institute on Drug Abuse
Application Receipt Date(s): March 3, 2016 by 5:00 PM local time of applicant organization

5.    Seek, Test, Treat and Retain For Youth and Young Adults Living with or at High Risk for Acquiring HIV (R01)

(RFA-DA-16-010)

National Institute on Drug Abuse

Application Receipt Date(s): March 2, 2016, by 5:00 PM local time of applicant organization.

 

1.    NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding

(NOT-OD-15-137)

National Institutes of Health

Office of AIDS Research

The purpose of this Notice is to inform the scientific community of the overarching HIV/AIDS research priorities and the guidelines NIH will use for determining AIDS funding beginning in fiscal year 2016 for the next three to five years. (Please read entire notice for details)

 

2.    Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01)
(RFA-DA-16-012)
National Institute on Drug Abuse
Application Receipt Date(s): March 02, 2016

The goal of this Funding Opportunity Announcement (FOA) is to stimulate innovative hypothesis-driven research to enhance our understanding of the role of epigenomic or non-coding RNA regulatory mechanisms in HIV/AIDS infection or disease trajectory in combination with substance use or abuse.  We are particularly interested in understanding regulatory mechanisms that influence selection and regulation of HIV sites of integration in the host genome.  A deeper understanding of these mechanisms could lead to novel approaches for monitoring latent HIV in cellular reservoirs, especially in the central nervous system.  Ultimately, research in this area could enable the identification of molecular targets that could be manipulated either to eliminate or permanently repress HIV in cellular reservoirs. (Please read entire Funding Opportunity Announcement for details

 

3.    Systems Biology Approaches in HIV/AIDS and Substance Use (R01)
(RFA-DA-16-013)
National Institute on Drug Abuse
Application Receipt Date(s): April 04, 2016

The purpose of this Funding Opportunity Announcement (FOA) is to support systems biology research projects that address critical questions in HIV/AIDS research in the context of drugs of abuse.  Substance use and abuse present unique challenges for HIV prevention, treatment, disease progression, medical consequences, potential cure, and responses to vaccines or therapeutics.  Understanding the complex biological intersection of HIV/AIDS and substance use and abuse is the central theme of this FOA.  (Please read entire Funding Opportunity Announcement for details)

 

 

4.    Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01)
(RFA-DA-16-014)
National Institute on Drug Abuse
Application Receipt Date(s): March 3, 2016 by 5:00 PM local time of applicant

The purpose of this FOA is to promote research to investigate the underlying molecular mechanisms by which HIV latency is initiated, established, and maintained in the CNS and to determine how drugs of abuse modulate HIV latency and the size and persistence of CNS HIV reservoirs. The ultimate goal is to obtain information for developing new or improved therapies for HIV treatment in drug-abusing populations. (Please read entire Funding Opportunity Announcement for details)

 

 

5.    Seek, Test, Treat and Retain For Youth and Young Adults Living with or at High Risk for Acquiring HIV (R01)

(RFA-DA-16-010)

National Institute on Drug Abuse

Application Receipt Date(s): March 2, 2016, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to examine seek, test, treat and retain approaches among youth and young adults (ages 13-25) who are at high risk for HIV acquisition or have already acquired HIV. Applications should incorporate substance use into study aims; objectives should address substance use prevention, screening, and/or treatment in ways that facilitate use of HIV prevention and treatment services. Youth are the target of this RFA because they demonstrate lower levels of screening and engagement across the HIV continuum of care and HIV+ youth are less likely to achieve viral suppression than those at older ages. These disparities are evident in US and foreign populations. The developmental, structural, and systemic factors related to serving youth need to be clearly incorporated into study aims, rather than simple incremental refocusing of existing interventions to younger people. Both domestic and international projects will be supported. (Please read entire Funding Opportunity Announcement for details)

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov     301-435-1309

 

 

 

2015-12-19

Re: [#DIV28SUPER] MA in clinical psychopharmacology at University of Hawai'i Hilo an APA designee

Great news!

Joseph D ( Dan) Eubanks, Ph. D., ABPP/CN
Kailua-Kona, Hawaii

_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28SUPER] MA in clinical psychopharmacology at University of Hawai'i Hilo an APA designee

The master of science in clinical psychopharmacology (MSCP) program offered through the Daniel K. Inouye College of Pharmacy at the University of Hawaiʻi at Hilo has been granted American Psychological Association (APA) designation.

http://www.hawaii.edu/news/2015/12/18/psychopharmacology-program-gains-apa-approval/

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

2015-12-18

[#DIV28SUPER] UVM NIH POSTDOCTORAL RESEARCH FELLOWSHIP POSITION

NIH Postdoctoral Research Fellowship Opportunity

The University of Vermont's Center on Behavior and Health announces an
NIH postdoctoral research fellowship opportunity in our
internationally recognized center of excellence for the study of
substance abuse. The fellow will participate in the conduct of an
ongoing NIDA-funded trial to develop a novel buprenorphine treatment
for opioid-dependent adults, as well as develop new research
opportunities in related areas. The mentoring team has an exceptional
track record of helping fellows further their careers as investigators.

Appointment: 2-3 yrs.

Eligibility: Applicants must have completed their training in
psychology, behavior analysis, or a related discipline and be U.S.
citizens or permanent residents. Trainees are selected on the basis
of scholastic record and commitment to a career in substance abuse
research. Individuals must be highly motivated, possess initiative and
a desire to learn and expand their interests and expertise.

Benefits: Stipend, medical insurance coverage, and travel funds
supported by NIH Institutional Training Awards.

For more information: Contact Ms. Diana Cain (Diana.Cain@uvm.edu).

To apply: Send cover letter (downloaded from VCBH website), curriculum
vitae, statement of research interests, and 3 letters of reference to:
Dr. Stacey Sigmon c/o Ms. Diana Cain (Diana.Cain@uvm.edu).

About us: The Vermont Center on Behavior and Health (VCBH) was
established in 2013, sponsored in part by a Centers of Biomedical
Research Excellence (COBRE) Award from the National Institute on
General Medical Sciences and a Centers of Tobacco Regulatory Science
(TCORS) Award from the National Institute on Drug Abuse.

The VCBH resides within the College of Medicine at the University of
Vermont, with the director and administrative offices being located
within the Department of Psychiatry, and participating investigators,
collaborators, and advisors across 15 academic departments in the
College of Medicine and 7 colleges within the University of Vermont
and5 other universities. The VCBH is further strengthened by
interdisciplinary collaborations with key community healthcare leaders
and distinguished scientific advisory panels.
The focus of the VCBH is on investigating relationships between
personal behaviors and risk for chronic disease and premature death,
with a specific focus on understanding mechanisms underpinning risk,
and developing effective interventions and policies to promote healthy
behavior.

See our website for further details:
https://www.uvm.edu/medicine/behaviorandhealth/

About Burlington, Vermont: Burlington, Vermont is located in the
beautiful Lake Champlain region, surrounded by the Green and
Adirondack Mountains. It is a great place for families, boasting
excellent schools and year-round recreational opportunities. It is
home to the University of Vermont and many other colleges that provide
an academically stimulating and culturally rich environment. Montreal
and Boston are within easy driving distances.

--
Stephen T. Higgins, Ph.D.
Director, Vermont Center on Behavior and Health
Professor and Virginia H. Donaldson Chair in Translational Science
Departments of Psychiatry and Psychology
Vice Chair, Department of Psychiatry
University of Vermont
1 South Prospect Street
Burlington, VT 05401-1419




_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28SUPER] APA questions Food & Drug Administration=?utf-8?Q?=E2=80=99s_?=draft rules for tobacco research

American Psychological Association

ronaldwood@gmail.com* thought you'd like to see the following from the American Psychological Association.


Page:
APA questions Food & Drug Administration's draft rules for tobacco research
http://www.apa.org/science/about/psa/2015/12/tobacco-research.aspx

* The sender's email address has not been verified.
www.apa.org | privacy statement | terms of use | contact APA

2015-12-17

[#DIV28SUPER] Call for Nominations - Division 28 Awards

Hello again!

I am writing to encourage you to submit nomination materials for APA Division 28 Awards for the 2016 APA meeting in Denver.  Attached you will find the official call for nominations with the detailed instructions for each of the three awards:  Med Associates Brady-Schuster Award, Young Psychopharmacologist Award and Outstanding Dissertation Award.  These awards are an excellent way to recognize your outstanding colleagues in science- both the young and more seasoned!  The Awards Committee looks forward to seeing this year’s nominees.  The deadline for materials is January 15, 2016.  

 

Regards and Happy Holidays!

 

Cathy Stanger

 

Catherine Stanger, Ph.D.

Associate Professor

Department of Psychiatry

Geisel School of Medicine at Dartmouth

Rivermill Complex

85 Mechanic Street

Suite B3-1, HB7549

Lebanon, NH 03766

Catherine.stanger@dartmouth.edu

Phone 603-653-1819

Fax 603-448-5335

 

2015-12-15

[#DIV28SUPER] Call for Articles for Special Issue

Dear Division 28 Members-

Please consider submitting a paper for the upcoming special issue of Experimental and Clinical Psychopharmacology.

Thanks,

Bill Stoops.


Call for Papers: Experimental and Clinical Psychopharmacology

 

Special Issue for August 2016 on:

50th Anniversary of APA Division 28: The Past, Present and Future of Psychopharmacology and Substance Abuse

 

Division 28 was formed in 1966 to provide a home within APA for psychologists interested in the behavioral effects of psychoactive or central nervous system drugs and chemicals.  Today, the Division's overarching mission is to encourage the advancement of knowledge on the behavioral effects of psychotropic drugs and toxicants, including (a) disseminating research-based information on psychopharmacology and substance abuse within APA, in educational settings, and to other scientists; (b) encouraging the application of the results of psychopharmacology research to human affairs; and (c) consideration of education and policy issues pertaining to psychopharmacology, behavioral toxicology, and substance abuse. 

 

During 2016, we will celebrate the 50th anniversary of Division 28. The proposed special issue will highlight the scientific contributions and historical milestones of APA's Division 28 and its members.  We invite manuscripts on the important scientific, clinical and translational contributions of Division 28 members, as well as commentary on the future of psychopharmacology and substance abuse research. In addition, collaborative, research-based manuscripts that disseminate new data about psychotropic drugs and toxicants are especially encouraged. Such papers could include novel research findings about the behavioral pharmacology of emerging drugs of abuse or newly developed compounds in non-human animals or humans (see [a], above). Research-based papers could also present new information on how aspects of psychopharmacology or substance abuse impact human affairs (see [b], above). Scholarly reflections on the notable changes that have occurred in the areas of psychopharmacology and substance abuse, particularly pertaining to education and policy (see [c], above), during the five decades since the Division was founded are also welcome.

 

Authors may submit primary research reports, review articles or commentaries to Experimental and Clinical Psychopharmacology to be considered for inclusion in this special issue. Manuscripts should be submitted as usual through the APA Online Submission Portal (www.apa.org/pubs/journals/pha/), and the cover letter should indicate that the authors wish the manuscript to be considered for publication in the special issue on the 50th Anniversary of Division 28.  All submissions will undergo our normal peer review. Manuscripts received no later than March 1, 2016 will be considered for inclusion in the special issue. We strongly encourage individuals to contact us in advance with their ideas and ideally a draft title and abstract.

 

Questions or inquiries about the special issue can be directed to the Guest Editors of the issue, William W. Stoops, PhD, at william.stoops@uky.edu or Stacey C. Sigmon, PhD at stacey.sigmon@uvm.edu.  Correspondence can also be directed to the Editor, Suzette M. Evans, PhD at se18@cumc.columbia.edu.


               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684


Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2015-12-14

[#DIV28SUPER] NIDA Neuroscience Update December 14, 2015

 

Table of Contents

I.                   Addiction Research: There's an App for that NOT-DA-15-080

II.                 BRAIN Initiative:  Non-Invasive Neuromodulation - New Tools and Techniques for Spatiotemporal Precision (R01) RFA-MH-16-810

III.              BRAIN Initiative:  Non-Invasive Neuromodulation - Mechanisms and Dose/Response Relationships for Targeted CNS Effects (R01) (RFA-MH-16-815)

IV.              BRAIN Initiative:  New Technologies and Novel Approaches for Large-Scale Recording and Modulation in the Nervous System (U01)  RFA-NS-16-006 

V.                BRAIN Initiative: Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01) RFA-NS-16-007

VI.              Funding opportunities issued for the NIH Precision Medicine Initiative® Cohort Program NOT-PM-16-001

 

 

I.             Addiction Research: There's an App for that NOT-DA-15-080

 

Deadline for Submission: April 29, 2016

Monetary prizes may be awarded: $50,000 1st place, $30,000 2nd place, $20,000 3rd place

 

Funding Opportunity Purpose

The National Institute on Drug Abuse (NIDA) announces a new Challenge/Prize Competition, "Addiction Research: There's an App for that" (https://www.federalregister.gov/articles/2015/11/03/2015-27939/national-institutes-of-health-national-institute-on-drug-abuse-nida-announcement-of-requirements-and)

The objective of this Challenge is to promote the development of innovative mobile applications (apps) for future addiction studies. The Challenge requires that the apps be explicitly created using Apple Inc.’s ResearchKit™, an open-source software kit designed specifically for biomedical and health research. NIDA encourages addiction researchers to use the newly available technical capabilities of ResearchKit™ and seek collaboration(s) with app developers and engineers to create the winning research app.

Please direct all inquiries to:

Elena Koustova, PhD, MBA
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-8768
Email:
elena.koustova@nih.gov

 

II.           BRAIN Initiative:  Non-Invasive Neuromodulation - New Tools and Techniques for Spatiotemporal Precision (R01)  (RFA-MH-16-810)
National Institute of Mental Health

Application Receipt Date: February 18, 2016, by 5:00 PM local time of applicant organization.

Funding Opportunity Purpose

 

This Funding Opportunity Announcement (FOA) solicits grant applications in two related but distinct areas.  The first area is in the development and testing of novel tools and methods of neuromodulation that go beyond the existing variations on magnetic or electrical stimulation, and that represent more than an incremental advance over existing electromagnetic approaches.  The second distinct area that this FOA seeks to encourage is the optimization of existing electrical and magnetic stimulation methods.   Please read entire announcement for further details.

 

III.          BRAIN Initiative:  Non-Invasive Neuromodulation - Mechanisms and Dose/Response Relationships for Targeted CNS Effects (R01) (RFA-MH-16-815)

Application Due Date: February 18, 2016, by 5:00 PM local time of applicant organization

Funding Opportunity Purpose

 

The focus of this Funding Opportunity Announcement (FOA) is to better understand how existing non-invasive neuromodulation devices affect brain circuity. This information should shed light on dose/response relationships that could be used for neuroscience applications and clinical interventions.  Please read entire announcement for details. Please read entire announcement for details.

 

IV.         BRAIN Initiative:  New Technologies and Novel Approaches for Large-Scale Recording and Modulation in the Nervous System (U01)  RFA-NS-16-006 

Application Due Date: February 24, 2016 by 5:00 PM local time of applicant organization.

Funding Opportunity Purpose

Understanding the dynamic activity of neural circuits is central to the NIH BRAIN Initiative.  This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for large-scale recording and manipulation of neural activity to enable transformative understanding of dynamic signaling in the nervous system.  In particular, we seek exceptionally creative approaches to address major challenges associated with recording and manipulating neural activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain.  It is expected that the proposed research may be high-risk, but if successful could profoundly change the course of neuroscience research.  

Proposed technologies should be compatible with experiments in behaving animals, and should include advancements that enable or reduce major barriers to hypothesis-driven experiments.  Technologies may engage diverse types of signaling beyond neuronal electrical activity for large-scale analysis, and may utilize any modality such as optical, electrical, magnetic, acoustic or genetic recording/manipulation.  Applications that seek to integrate multiple approaches are encouraged.  Where appropriate, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.  Please read entire announcement for further details.

 

V.          BRAIN Initiative: Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01)RFA-NS-16-007

Funding Opportunity Purpose

Although invention and proof-of-concept testing of new technologies is a key component of the BRAIN Initiative, to achieve their potential these technologies must also be optimized through feedback from end-users in the context of the intended experimental use. This seeks applications for the optimization of existing and emerging technologies and approaches that have potential to address major challenges associated with recording and manipulating neural activity, at or near cellular resolution, at multiple spatial and temporal scales, in any region and throughout the entire depth of the brain.  This FOA is intended for the iterative refinement of emergent technologies and approaches that have already demonstrated their transformative potential through initial proof-of-concept testing, and are appropriate for accelerated development of hardware and software while scaling manufacturing techniques towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience practice. 

Proposed technologies should be compatible with experiments in behaving animals, and should include advancements that enable or reduce major barriers to hypothesis-driven experiments.  Technologies may engage diverse types of signaling beyond neuronal electrical activity for large-scale analysis, and may utilize any modality such as optical, electrical, magnetic, acoustic or genetic recording/manipulation.  Applications that seek to integrate multiple approaches are encouraged.  Applications are expected to integrate appropriate domains of expertise, including where appropriate biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.    Please read entire announcement for further details.

 

 

VI.              Funding opportunities issued for the NIH Precision Medicine Initiative® Cohort Program NOT-PM-16-001

Key Dates
Release Date: November 25, 2015

Related Announcements
NOT-OD-15-159 Precision Medicine Initiative Cohort Program Recommendations Issued and Accepted
RFA-PM-16-001 Precision Medicine Initiative® Cohort Program Coordinating Center (U2C)
RFA-PM-16-002 Precision Medicine Initiative® Cohort Program Healthcare Provider Organization Enrollment Centers (UG3/UH3)
RFA-PM-16-003 Precision Medicine Initiative® Cohort Program Participant Technologies Center (U24)
RFA-PM-16-004 Precision Medicine Initiative® Cohort Program Biobank (U24)
PM-OT-16-001   Precision Medicine Initiative® Cohort Program Direct Volunteers Pilot Studies
PM-OT-16-002   Communication Support for the Precision Medicine Initiative® Research Programs at NIH    

Issued by
Office of Strategic Coordination (
Common Fund)

Purpose

On November 17, the NIH issued the first set of funding opportunities associated with the implementation of the NIH Precision Medicine Initiative ® (PMI) Cohort Program. These included four (4) funding opportunity announcements for cooperative agreements, and two (2) funding opportunities for Other Transaction awards. 

Together, the projects these funding opportunities support will build a solid infrastructure for the PMI Cohort Program.  The cooperative agreements will support a coordinating center (RFA-PM-16-001), network of healthcare provider organizations (RFA-PM-16-002), participant mobile technologies (RFA-PM-16-003), and a biobank (RFA-PM-16-004). The Other Transaction awards will develop a pilot program to inform the creation of the direct volunteer enrollment component of the cohort (OT-PM-16-001), and develop a communication infrastructure that will be vital to conveying the importance of this research effort (OT-PM-16-002).

Links to all funding opportunities supporting the PMI Cohort Program may be accessed through the NIH PMI website's Funding Opportunities page: http://www.nih.gov/precision-medicine-initiative-cohort-program/funding-opportunities.

Inquiries

Please direct all inquiries to:

Irene Haas
PMI Cohort Program Agreements Officer
Email:
PMICPFOAInquiries@mail.nih.gov

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contactjpollock@mail.nih.gov 301-435-1309

 

2015-12-08

[#DIV28SUPER] JSAT Special Issue on Contingency Management: Call for Papers

CALL FOR PAPERS:
 
SPECIAL ISSUE OF THE JOURNAL OF SUBSTANCE ABUSE TREATMENT
 
Contingency Management in Substance Use Treatment
 
The Journal of Substance Abuse Treatment is requesting submissions for a special issue of research studies on the use of Contingency Management Interventions in Substance Use Treatment. The DEADLINE FOR SUBMISSION is February 1, 2016. Early submissions are welcome.
Interested authors should contact one of the Guest Editors for the special issue, Carla J. Rash (rashc@uchc.edu), Jeremiah Weinstock (jweinsto@slu.edu), or Maxine L. Stitzer (mstitzer@jhmi.edu) for more information. Manuscripts should be submitted via the Elsevier Editorial System's website for JSAT (http://ees.elsevier.com/jsat/) as a "Special Issue Paper" and the Cover Letter should also indicate that the manuscript is intended for the special issue. Author guidelines are available online. Manuscripts submitted for the special issue will be screened by the guest editors before being sent out for peer review.
 
Contingency management (CM) is a behavioral intervention that has been especially useful and effective in the treatment of substance use disorders. While CM's efficacy is well established, its adoption and implementation in real world clinical settings is limited. Questions remain regarding clinician attitudes, funding models, training and implementation practices, methods to extend CM effects beyond the time of application, novel behavioral targets of reinforcement, and mechanisms of action. We seek papers that extend our scientific knowledge of CM in these and other areas and/or address barriers to CM's growth as a clinical intervention.
 
JSAT invites original research studies, research-based systematic reviews, and empirically-informed conceptual papers relevant to the special issue that will focus on CM interventions in substance use treatment. Primary and secondary outcome analyses that advance the field are welcome. Topics of interest include, but are not limited to: 1) outcome studies using CM to reduce substance use; 2) outcome studies using CM to alter other behavioral targets related to substance use; 3) CM studies involving novel adaptations, populations, or settings; 4) studies examining CM's mechanisms of action; 5) dissemination and implementation studies, including topics related to assessment, training, use of technology, and delivery of CM; 6) cost-analysis studies related to CM; 7) clinical demonstrations of CM; and 8) conceptual papers that identify key barriers and potential solutions to widespread implementation and sustainment of CM.

 

2015-12-04

[#DIV28SUPER] UVM NIH POSTDOCTORAL RESEARCH FELLOWSHIP POSITION

NIH Postdoctoral Research Fellowship Opportunity

The University of Vermont's Center on Behavior and Health announces an
NIH postdoctoral research fellowship opportunity in our
internationally recognized center of excellence for the study of
substance abuse. The fellow will participate in the conduct of an
ongoing NIDA-funded trial to develop a novel buprenorphine treatment
for opioid-dependent adults, as well as develop new research
opportunities in related areas. The mentoring team has an exceptional
track record of helping fellows further their careers as investigators.

Appointment: 2-3 yrs.

Eligibility: Applicants must have completed their training in
psychology, behavior analysis, or a related discipline and be U.S.
citizens or permanent residents. Trainees are selected on the basis
of scholastic record and commitment to a career in substance abuse
research. Individuals must be highly motivated, possess initiative and
a desire to learn and expand their interests and expertise.

Benefits: Stipend, medical insurance coverage, and travel funds
supported by NIH Institutional Training Awards.

For more information: Contact Ms. Diana Cain (Diana.Cain@uvm.edu).

To apply: Send cover letter (downloaded from VCBH website), curriculum
vitae, statement of research interests, and 3 letters of reference to:
Dr. Stacey Sigmon c/o Ms. Diana Cain (Diana.Cain@uvm.edu).

About us: The Vermont Center on Behavior and Health (VCBH) was
established in 2013, sponsored in part by a Centers of Biomedical
Research Excellence (COBRE) Award from the National Institute on
General Medical Sciences and a Centers of Tobacco Regulatory Science
(TCORS) Award from the National Institute on Drug Abuse.

The VCBH resides within the College of Medicine at the University of
Vermont, with the director and administrative offices being located
within the Department of Psychiatry, and participating investigators,
collaborators, and advisors across 15 academic departments in the
College of Medicine and 7 colleges within the University of Vermont
and5 other universities. The VCBH is further strengthened by
interdisciplinary collaborations with key community healthcare leaders
and distinguished scientific advisory panels.
The focus of the VCBH is on investigating relationships between
personal behaviors and risk for chronic disease and premature death,
with a specific focus on understanding mechanisms underpinning risk,
and developing effective interventions and policies to promote healthy
behavior.

See our website for further details:
http://www.uvm.edu/medicine/behaviorandhealth/

About Burlington, Vermont: Burlington, Vermont is located in the
beautiful Lake Champlain region, surrounded by the Green and
Adirondack Mountains. It is a great place for families, boasting
excellent schools and year-round recreational opportunities. It is
home to the University of Vermont and many other colleges that provide
an academically stimulating and culturally rich environment. Montreal
and Boston are within easy driving distances.


Stephen T. Higgins, Ph.D.
Director, Vermont Center on Behavior and Health
Professor and Virginia H. Donaldson Chair in Translational Science
Departments of Psychiatry and Psychology
Vice Chair, Department of Psychiatry
University of Vermont
1 South Prospect Street
Burlington, VT 05401-1419




_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28M] call for submissions

Dear Colleagues,
Please consider submitting your work to Experimental and Clinical Psychopharmacology. More information about the journal is below.
-Bill.

Experimental and Clinical Psychopharmacology

 

Our goal is to improve the quality and speed of the review process, as well as the quality and breadth of manuscripts published in Experimental and Clinical Psychopharmacology.  Here are some of the reasons why you, your colleagues, trainees and students should submit your research to Experimental and Clinical Psychopharmacology:

 

Highlights

·      Rapid Turnaround: The average speed from submission to initial decision letter is 21 days

·      Impact Factor: The 2014 impact factor was 2.712 compared to 2.626 in 2013

·      Favorable Rate of Acceptance:  Approximately 40-50% of manuscripts submitted are accepted

·      No Set Page Restrictions: There is no a priori limit on the number of words, tables, figures or references, but manuscript length should be reasonable given the nature of the study and findings.

 

Mission

Experimental and Clinical Psychopharmacology (ECP) publishes advances in translational and interdisciplinary research on psychopharmacology and drug abuse. The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, brain imaging, genetics, neuroendocrinology, neuroscience, and pharmacology.  One goal of the journal is to encourage increased attention to biologic factors that may influence both the pharmacodynamic and the pharmacokinetic effects of drugs. Recent research has shown the importance of examining the effects of sex and menstrual/estrous cycle phase on the effects of abused drugs, as well as responses to medications for the treatment of drug abuse and the alleviation of pain.  The journal publishes original reports on the development and evaluation of new pharmacotherapies, the influence of genetics and hormones on responses to abused drugs and treatment medications, the pharmacological management of pain, and brain imaging studies of the neural correlates of drug effects.  The journal will focus on clinical laboratory studies and controlled clinical medication trials as well as basic preclinical experiments on psychopharmacology and drug abuse.  The journal also will include comprehensive and integrative reviews of advances in research on psychopharmacology. These reviews should provide a broad perspective on a particular area of research or trace the development of critical concepts and experimental approaches.

 

Submit your manuscripts to:

 

www.apa.org/pubs/journals/pha/

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684


Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

[#DIV28M] Call for Nominations

Dear Division 28 Members-
I have attached the Call for Nominations for a new editor for Experimental and Clinical Psychopharmacology, beginning service in 2017. Please consider nominating yourself or a colleague.
-Bill Stoops.

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684


Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2015-12-03

[#DIV28SUPER] Call for Nominations - Division 28 Awards

Dear Colleagues:

I am writing to encourage you to submit nomination materials for APA Division 28 Awards for the 2016 APA meeting in Denver.  Attached you will find the official call for nominations with the detailed instructions for each of the three awards:  Med Associates Brady-Schuster Award, Young Psychopharmacologist Award and Outstanding Dissertation Award.  These awards are an excellent way to recognize your outstanding colleagues in science- both the young and more seasoned!  The Awards Committee looks forward to seeing this year’s nominees.  The deadline for materials is January 15, 2016.  

 

Regards,

 

Cathy Stanger

 

Catherine Stanger, Ph.D.

Associate Professor

Department of Psychiatry

Geisel School of Medicine at Dartmouth

Rivermill Complex

85 Mechanic Street

Suite B3-1, HB7549

Lebanon, NH 03766

Catherine.stanger@dartmouth.edu

Phone 603-653-1819

Fax 603-448-5335

 

2015-12-02

[#DIV28SUPER] APA Division 28 newsletter

 

Good afternoon. Attached is the final 2015 issue of the APA Division 28 newsletter.

 

Mikhail Koffarnus

Virginia Tech Carilion Research Institute

2 Riverside Circle

Roanoke, VA 24016

540.526.2107

[#DIV28SUPER] NIDA Women and Sex/Gender Differences Junior Investigator Travel Award Program at CPDD 2016

 

NIDA’s  Women and Sex/Gender Differences Junior Investigator Travel Award Program

at the 2016 College on Problems of Drug Dependence meeting

Considerable research, both human and animal, finds that the antecedents, consequences and mechanisms of drug abuse and dependence often differ between males and female and that sex/gender often plays a role in treatment and prevention outcomes.  To help promote comparisons of outcomes in males and females and to promote female-specific research, NIDA plans to provide $1000 travel awards to 20 junior investigators who present their research on women or sex/gender analyses in any area of drug abuse at the annual CPDD meeting in Palm Springs, California, June 11-16. 

 

    Eligibility:

·         Graduate and medical students, post-doctoral students, medical residents, and investigators who are no more

        than five years past the doctoral degree or residency are eligible.

·         Applicant MUST be first author on the CPDD abstract or an oral symposium presentation.

·         Minority investigators and male investigators are especially encouraged to apply.

·         Priority may be given to those who have not previously received this award or held an R01.

·         Federal employees are ineligible.

 

electronic Application Procedures:

Follow the CPDD instructions for abstract submission.  Then send an e-mail to Christie Espinoza at espinozac@nida.nih.gov  in the following format and with the required attachments:

·         E-mail subject line: CPDD 2016 Women & Sex/Gender Junior Investigator Travel Award Application

·         Attach a copy of the abstract that you submitted to CPDD, including title and authors (in Word format).

·         Attach your curriculum vitae (in Word format).  List all NIH grant support if applicable.  Include your mailing

        address, phone number and e-mail address.

·         Attach a cover letter (in Word format) stating (1) your eligibility, (2) your interest in continuing to pursue research

on women and/or sex/gender differences, and (3) your career goals.

 

Deadline for applications:  December 7, 2015

For additional information about this annual award, contact Dr. Cora Lee Wetherington, cwetheri@nida.nih.gov, Phone 301-435-1319.      

 

 

Cora Lee Wetherington, Ph.D.

Women & Sex/Gender Differences Research Coordinator, NIDA

Division of Neuroscience & Behavior

National Institute on Drug Abuse

6001 Executive Blvd., Suite 4282, MSC 9555

Bethesda, MD 20892-9555 (For overnight mail:  Rockville, MD 20852) 

Phone:  (301) 435-1319

Fax:  (301) 443-6043

E-mail: cwetheri@nida.nih.gov